前收盘价格 | 0.579 |
收盘价格 | 0.600 |
成交量 | 1,525,832 |
平均成交量 (3个月) | 1,182,090 |
市值 | 1,994,977,664 |
价格/销量 (P/S) | 217.34 |
股市价格/股市净资产 (P/B) | 97.15 |
52周波幅 | |
利润日期 | 12 May 2025 |
营业利益率 (TTM) | -17,994.78% |
稀释每股收益 (EPS TTM) | -0.590 |
总债务/股东权益 (D/E MRQ) | 0.91% |
流动比率 (MRQ) | 10.96 |
营业现金流 (OCF TTM) | -121.30 M |
杠杆自由现金流 (LFCF TTM) | -114.20 M |
资产报酬率 (ROA TTM) | -28.29% |
股东权益报酬率 (ROE TTM) | -45.28% |
市场趋势
短期 | 中期 | ||
行业 | Biotechnology (US) | 看跌 | 看跌 |
Biotechnology (全球的) | 看跌 | 看跌 | |
股票 | ProKidney Corp. | 看跌 | 看跌 |
AIStockmoo 评分
-1.0
分析师共识 | -0.5 |
内部交易活动 | NA |
价格波动 | 0.5 |
技术平均移动指标 | -1.5 |
技术振荡指标 | -2.5 |
平均 | -1.00 |
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease. |
|
部门 | Healthcare |
行业 | Biotechnology |
内部持股比例 | 30.05% |
机构持股比例 | 41.66% |
所有权
姓名 | 日期 | 持有股份 |
---|---|---|
Brown University | 31 Mar 2025 | 1,000,000 |
52周波幅 | ||
中 | 1.00 (56.94%) | |
总计 | 1 卖出 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
B of A Securities | 30 Jun 2025 | 1.00 (56.94%) | 卖出 | 0.592 |
该时间范围内无数据。
日期 | 类型 | 细节 |
---|---|---|
01 Jul 2025 | 公告 | ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware |
12 May 2025 | 公告 | ProKidney Reports First Quarter 2025 Financial Results and Business Highlights |
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合